

**Supplemental Table 1** Summary of the participants received colonoscopy or histopathological examinations.

Group	Diseases	Colonoscopy	Histological	Total	
Normal		300	0	300	
	Anal cancer	0	1	1	
	Appendix cancer	1	1	2	
	Colon polypus	1	72	73	
	Coloproctitis	31	139	170	
	Diverticulum	15	1	16	
	Interfering diseases	Esophagitis	0	1	1
		Gastric polyps	11	1	12
		Gastritis	13	2	15
		Hemorrhoids	65	5	70
Liver cancer		0	2	2	
Stomach cancer		0	6	6	
Other		18	10	28	
Non-advanced adenoma		0	110	110	
Adenoma	Advanced adenoma	0	38	38	
CRC		0	320	320	
Total		455	709	1164	

**Note:** if the participants received both colonoscopy and histopathological examinations, we only used the histopathological examinations to determine their disease status.

**Supplementary Table 2** Performance of methylated *SDC2* and *TFPI2* in detection of CRCs and other groups.

Traget	Sensitivity (%)	Specificity (%)	AUC(95%CI)	Compared group
SDC2	71.74	96.2	0.84(0.81~0.86)	All non-CRC vs CRC
TFPI2	83.85	88.95	0.86(0.84~0.89)	All non-CRC vs CRC
Dual-target	95.34	88.36	0.92(0.90~0.93)	All non-CRC vs CRC
SDC2	71.74	100	0.86(0.84~0.88)	Normal vs CRC
TFPI2	83.85	96.67	0.90(0.88~0.93)	Normal vs CRC
Dual-target	95.34	96.67	0.96(0.94~0.97)	Normal vs CRC
SDC2	18.24	100	0.59(0.56~0.63)	Normal vs Adenoma
TFPI2	39.19	96.67	0.68(0.64~0.71)	Normal vs Adenoma
Dual-target	41.22	96.67	0.69(0.66~0.73)	Normal vs Adenoma
SDC2	36.84	100	0.68(0.61~0.77)	Normal vs Advanced adenoma
TFPI2	57.89	96.67	0.77(0.70~0.84)	Normal vs Advanced adenoma
Dual-target	63.16	96.67	0.80(0.73~0.87)	Normal vs Advanced adenoma
SDC2	11.82	100	0.56(0.53~0.59)	Normal vs Non-advanced adenoma
TFPI2	32.73	96.67	0.65(0.61~0.69)	Normal vs Non-advanced adenoma
Dual-target	33.64	96.67	0.65(0.62~0.70)	Normal vs Non-advanced adenoma
SDC2	73.01	100	0.87(0.83~0.90)	Normal vs Stage I-II
TFPI2	81.6	96.67	0.89(0.87~0.92)	Normal vs Stage I-II
Dual-target	96.93	96.67	0.97(0.95~0.98)	Normal vs Stage I-II

SDC2	69.18	100	0.85(0.81~0.88)	Normal vs Stage III-IV
TFPI2	84.93	96.67	0.91(0.88~0.94)	Normal vs Stage III-IV
Dual-target	93.15	96.67	0.95(0.92~0.97)	Normal vs Stage III-IV

**Supplementary Table 3** Performance of the DT-sDNA test in discriminating interfering diseases from CRCs.

Interfering diseases	Subject (% , n)	Positive detection rate (% , n)	Specificity (% , n)
Colon polypus	18.53 (73)	2.23% (9)	87.67 (64)
Coloproctitis	42.89 (169)	2.48% (10)	94.08 (159)
Diverticulum	4.06 (16)	0.25% (1)	93.75 (15)
Esophagitis	0.25 (1)	0 (0)	100 (1)
Gastric polyps	3.05 (12)	0 (0)	100 (12)
Gastritis	3.81 (15)	0 (0)	100 (15)
Hemorrhoids	17.77 (70)	0.99% (4)	94.29 (66)
Liver cancer	0.51 (2)	0 (0)	100 (2)
Stomach cancer	1.27 (5)	0.25% (1)	80 (4)
Appendix cancer	0.51 (2)	0 (0)	100 (2)
Anal cancer	0.25 (1)	0 (0)	100 (1)
Other	7.11 (28)	0.5% (2)	92.86 (26)
<b>Total</b>	<b>100 (394)</b>	<b>6.70% (27)</b>	<b>93.15 (367)</b>

**Supplementary Table 4** Retested results of 34 resected patients by DT-sDNA test.

		Before resected	
		Positive	Negative
After resected	Positive	2	0
	Negative	28	4

**Supplementary Table 5** Performance of CEA and CA19-9 for CRC detection.

	CEA				CA19-9			
	Negative	Positive	Sensitivity	Specificity	Negative	Positive	Sensitivity	Specificity
Healthy control	88	11	0.29	0.89	74	7	0.12	0.91
CRC	112	45			131	17		